Add Yahoo as a preferred source to see more of our stories on Google. A screen displays the logo and trading information for Eli Lilly and Company on the floor at the New York Stock Exchange (NYSE) in ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...

Eli Lilly (NYSE: LLY) wasn't the first to market with a GLP-1 drug. However, its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs have proven more effective than competing products. That's ...

Eli Lilly (LLY) announced on Wednesday that a late-stage trial designed to test a combination regimen containing its weight loss therapy Zepbound and psoriasis therapy Taltz reached the main goals.

Hims & Hers Health began advertising a $49 Ozempic pill lookalike last week -- then stopped. Novo Nordisk charges $149 for its own Wegovy pills. Lilly charges $299 for Zepbound shots. First, on Friday ...

Eli Lilly’s stock closed 10.3% higher on Wednesday after the drug giant reported triple-digit growth of Zepbound and Mounjaro, its game-changing weight-loss and Type 2 diabetes drugs. That’s the third ...

Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ...

Eli Lilly is rated SELL due to lofty valuation, despite extraordinary execution and recent market leadership in GLP-1 and obesity drugs. LLY's current $950B market cap implies sustained 25% annual ...

Eli Lilly LLY0.80%increase; green up pointing triangle reported higher fourth-quarter profit on the back of surging demand for its GLP-1 weight-loss drugs. The pharmaceutical company reported net ...

Eli Lilly posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The ...

Profit and revenue forecasts for 2026 well above Street view Lilly's Q4 profit and revenue exceed expectations Lilly's obesity drug Zepbound boosts sales despite price cuts Lilly's orforglipron pill ...

Eli Lilly & Co. struck a deal worth more than $1.1 billion with German biotech Seamless Therapeutics GmbH to develop gene therapies for hearing loss. Closely-held Seamless will design a type of enzyme ...